Virpax And MedPharm Advance Diclofenac Spray
Transdermal Osteoarthritis Treatment To Be Submitted Via 505(b)(2) Pathway In US
Virpax Pharmaceuticals and partner MedPharm say they have made progress towards filing through the US 505(b)(2) hybrid pathway a diclofenac spray for treating osteoarthritis of the knee.
You may also be interested in...
UK firm opens site in North Carolina’s Research Triangle Park to expand its contract formulation development services for OTC and Rx topical and transdermal products. It has supported projects with six of the eight leading OTC companies.
Public Company Edition: Merging with a special purpose acquisition corporation may be an attractive alternative to an initial public offering, but February’s vigorous IPO pace includes seven recent offerings that raised $480.8m in the US. Also, Cassava raised $200m and KalVista brought in $222.5m.
Amzell has revealed trial results indicating that its diclofenac 3.06% gel formulation is effective for treating knee osteoarthritis symptoms.